ADAP News and Press, Adaptimmune Therapeutics plc From 05/06/19

Thinly traded micro cap Adaptimmune Therapeutics (NASDAQ: ADAP ) is up  6%  premarket on average volume in reaction to preliminary data in a pilot study of T-cell therapy candidate ADP-A2M4 . More news on: Adaptimmune Therapeutics plc, Healthcare stocks news, Read more ......

Aquantia (NYSE: AQ ) +36%  on $452M sale to Marvell. More news on: Aquantia Corp., Ovid Therapeutics Inc., Adaptimmune Therapeutics plc, Stocks on the move, Read more ...

Adaptimmune (NASDAQ: ADAP ): Q1 GAAP EPS of -$0.04  beats by $0.27 . Cash and cash equivalentS of $49.9M. Press Release More news on: Adaptimmune Therapeutics plc, Earnings news and commentary, Healthcare stocks news,

- Clinical update issued in a separate announcement - - Financial guidance updated: funded into Q3 2020 - PHILADELPHIA and OXFORD, United Kingdom, May 06, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported fin...

- Partial responses in 4 out of 5 synovial sarcoma patients treated with ~10 billion cells, with tumor shrinkage in nearly all assessed synovial sarcoma patients in the ADP-A2M4 pilot study -              - Initiating SPEARHEAD-1 trial in synovial sarcom...

- Data show strong progress with off-the-shelf program demonstrating T-cell differentiation from stem cells (hiPSC) in a serum-free process without the addition of mouse stromal cells - - Lentiviral transduction of hiPSC-derived cells with a SPEAR TCR produces transduced T-cells that...

PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 01, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will provide a clinical and business update before the U.S. markets open on Monday May 6, 2019. Following the announcem...

- Presentation to include overview of substantial progress of Adaptimmune’s off-the-shelf SPEAR T-cell platform - - Data will show that hiPSC-derived allogeneic SPEAR T-cells have a T-cell phenotype and demonstrate tumor antigen-specific activation in vitro - PHILADELPHIA and OX...

PHILADELPHIA and OXFORD, United Kingdom, April 02, 2019 (GLOBE NEWSWIRE) --  Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented initial safety data from two patients with advanced hepatocellular carcinoma (HCC), liver cancer, from the...

PHILADELPHIA and OXFORD, United Kingdom, April 01, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, presented promising preclinical data at the annual AACR meeting from its next generation SPEAR T-cell targeting MAGE-A4. T...